Nick Train doubles down on Finsbury Growth & Income's worst performer

Sticking to Fever-Tree ‘makes sense’

Valeria Martinez
clock • 2 min read

Manager of the Finsbury Growth and Income trust Nick Train has increased his position in Fever-Tree, despite the soft drinks manufacturer delivering the worst performance across the portfolio in July.

In the latest monthly report, Train revealed he had bought more shares in the beverage producer after they fell 12% on a profit warning related to transportation and glass costs ahead of its H1 results.  Nick Train uses DMGT cash to top up Fever-Tree and Experian The manager said he is confident about the company's secular growth opportunity in all its markets, especially in the US, and applauded management for "doing the right thing for the business". "It would be quite wrong for the company to protect its profit margins in current circumstances," he said. Such measures could incl...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Investment

Advisers zoomed in on capital accumulation in Q4 2025

Advisers zoomed in on capital accumulation in Q4 2025

Titan Square Mile research finds

Jen Frost
clock 30 January 2026 • 3 min read
Measure for measure: How to track your tracker fund

Measure for measure: How to track your tracker fund

Tracking difference and tracking error

Terry McGivern
clock 28 January 2026 • 3 min read
SJP and AJ Bell pivot from US mega-caps in MPS as concentration woes continue

SJP and AJ Bell pivot from US mega-caps in MPS as concentration woes continue

Healthcare, energy and EM preferred

Linus Uhlig
clock 28 January 2026 • 2 min read